Glaukos (NYSE:GKOS) CFO Alex Thurman Sells 2,511 Shares

Glaukos Corporation (NYSE:GKOS) CFO Alex Thurman sold 2,511 shares of Glaukos stock in a transaction that occurred on Wednesday, March 25th. The shares were sold at an average price of $106.46, for a total transaction of $267,321.06. Following the sale, the chief financial officer owned 41,967 shares in the company, valued at approximately $4,467,806.82. The trade was a 5.65% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Glaukos Stock Performance

NYSE GKOS opened at $103.13 on Friday. Glaukos Corporation has a 1-year low of $73.16 and a 1-year high of $130.23. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.69 and a quick ratio of 4.06. The business has a 50 day simple moving average of $112.94 and a two-hundred day simple moving average of $101.97. The stock has a market capitalization of $5.99 billion, a PE ratio of -31.63 and a beta of 0.70.

Glaukos (NYSE:GKOS) last issued its quarterly earnings data on Tuesday, February 17th. The medical instruments supplier reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.06). The business had revenue of $143.12 million during the quarter, compared to analysts’ expectations of $132.16 million. Glaukos had a negative return on equity of 7.00% and a negative net margin of 36.99%.The business’s quarterly revenue was up 35.6% on a year-over-year basis. During the same period in the previous year, the business earned ($0.40) earnings per share. On average, research analysts predict that Glaukos Corporation will post -1.08 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Smartleaf Asset Management LLC boosted its holdings in Glaukos by 9.7% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,383 shares of the medical instruments supplier’s stock valued at $158,000 after acquiring an additional 122 shares during the period. Larson Financial Group LLC lifted its stake in Glaukos by 62.0% during the fourth quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock worth $39,000 after purchasing an additional 132 shares during the last quarter. CWM LLC lifted its stake in Glaukos by 25.2% during the fourth quarter. CWM LLC now owns 710 shares of the medical instruments supplier’s stock worth $80,000 after purchasing an additional 143 shares during the last quarter. Commonwealth Equity Services LLC lifted its position in Glaukos by 1.7% in the fourth quarter. Commonwealth Equity Services LLC now owns 8,383 shares of the medical instruments supplier’s stock valued at $947,000 after acquiring an additional 144 shares during the last quarter. Finally, Evergreen Capital Management LLC boosted its stake in Glaukos by 4.3% in the fourth quarter. Evergreen Capital Management LLC now owns 3,549 shares of the medical instruments supplier’s stock valued at $401,000 after acquiring an additional 145 shares in the last quarter. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on GKOS. Stephens increased their price target on Glaukos from $115.00 to $145.00 and gave the stock an “overweight” rating in a report on Friday, January 2nd. Wells Fargo & Company upped their target price on Glaukos from $122.00 to $135.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. William Blair raised Glaukos to a “strong-buy” rating in a research report on Friday, January 30th. UBS Group boosted their target price on shares of Glaukos from $140.00 to $145.00 and gave the stock a “buy” rating in a research report on Tuesday, December 23rd. Finally, BTIG Research reiterated a “buy” rating and issued a $131.00 target price on shares of Glaukos in a research report on Wednesday, February 18th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Glaukos currently has a consensus rating of “Moderate Buy” and a consensus target price of $133.69.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.